<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02063763</url>
  </required_header>
  <id_info>
    <org_study_id>ITP0614</org_study_id>
    <nct_id>NCT02063763</nct_id>
  </id_info>
  <brief_title>TPO-mimetics Before Splenectomy in Adult Primary Immune Thrombocytopenia Patients.</brief_title>
  <acronym>ITP0614</acronym>
  <official_title>Use of TPO-mimetics to Prepare for Splenectomy in Adult Patients With Primary Immune Thrombocytopenia. Brooklyn Observational Retrospective Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at analyzing the therapeutic activity of TPO-mimetics Eltrombopag and&#xD;
      Romiplostim as bridge therapy for splenectomy in adult patients with primary immune&#xD;
      thrombocytopenia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult immune primary thrombocytopenia is an autoimmune malignancy characterized by platelet&#xD;
      destruction and inadequate platelet production. Its incidence is of three cases per 100,000&#xD;
      people a year, with a prevalence in women in young and older adults.&#xD;
&#xD;
      Splenectomy is, still today, the therapeutic approach that offers a bigger guarantee of a&#xD;
      long term response (around 60+70%). Nevertheless, splenectomy may be accompanied by&#xD;
      peri-operative complications in almost 10% of patients, which in rare cases may be fatal.&#xD;
      These are normally hemorrhagic complications due to low platelet count. Thus, a previous&#xD;
      therapy to increase platelets is advisable before any splenectomy.&#xD;
&#xD;
      In patients who are refractory to corticosteroids and immunoglobulins or when its use is not&#xD;
      indicated, splenectomy has a potential risk of more complications. Since the last few years,&#xD;
      we count with TPO-mimetic drugs, specific for c-MPL receptor, able to stimulate platelet&#xD;
      production, such as romiplostim and eltrombopag.&#xD;
&#xD;
      Nowadays, TPO-mimetics are allowed in Italy when patients refuse splenectomy or when&#xD;
      splenectomy is not contraindicated, but being ITP with a low platelet count (&lt; 20-50.000/mmc)&#xD;
      a potential contraindication to splenectomy due to hemorrhagic events, these drugs should be&#xD;
      considered. Nevertheless, there are no data on therapeutic risks and safety of these agents&#xD;
      when used for this indication. The aim of the present study is to verify, on an Italian&#xD;
      national scale, the frequency of use, its impact and the safety profile.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 14, 2014</start_date>
  <completion_date type="Actual">February 26, 2015</completion_date>
  <primary_completion_date type="Actual">February 26, 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients responding to TPO-mimetics</measure>
    <time_frame>Six months.</time_frame>
    <description>According to platelet count and presence or absence of hemorrhagic events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients on TPO-mimetics eltrombopag and romiplostim as bridge therapy before splenectomy.</measure>
    <time_frame>Six months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and ways of administration.</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hemorrhagic events.</measure>
    <time_frame>At thirty days from splenectomy.</time_frame>
    <description>Number and seriousness of hemorrhagic, thrombotic and infectious events at 30 days from splenectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of toxicity.</measure>
    <time_frame>Six months</time_frame>
    <description>NCI CTCAE v. 4.0</description>
  </secondary_outcome>
  <enrollment type="Actual">31</enrollment>
  <condition>Adult Patients</condition>
  <condition>Immune Primary Thrombocytopenia</condition>
  <condition>Splenectomy</condition>
  <condition>TPO-mimetics</condition>
  <eligibility>
    <study_pop>
      <textblock>
        ITP adult patients having undergone splenectomy after a bridge therapy with eltrombopag or&#xD;
        romiplostim.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Persistent or chronic ITP in symtomatic phase.&#xD;
&#xD;
          -  18 years of age or older.&#xD;
&#xD;
          -  Indication for splenectomy due to refractory response to a previous therapy.&#xD;
&#xD;
          -  Have used eltrombopag or romiplostim to increase platelet count before splenectomy.&#xD;
&#xD;
          -  Have undergone splenectomy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Zaja, Pr.</last_name>
    <role>Study Chair</role>
    <affiliation>Clinica Ematologica, DISM, Azienda Ospedaliera Universitaria S. M. Misericordia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.O.C di Ematologia P.O. &quot;S.Giuseppe Moscati&quot;</name>
      <address>
        <city>Aversa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOC Ematologia Ospedale &quot; Mons. Dimiccoli&quot;</name>
      <address>
        <city>Barletta</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico di Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Complessa) - Medicina Generale - Sezione di Ematologia - Ospedale Versilia USL 12 Toscana</name>
      <address>
        <city>Lido di Camaiore</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico UOC Oncoematologia- Padiglione Marcora 2° piano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Niguarda &quot; Ca Granda&quot; - SC Ematologia Blocco SUD, Ponti Est, Scala E, 4° piano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Trapianto di Midollo Ist. Nazionale Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;S.Gerardo&quot;</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi &quot;Sapienza&quot; - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Santa Maria - Terni S.C Oncoematologia</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica - Policlinico Universitario</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.gimema.it</url>
    <description>GIMEMA Foundation</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 13, 2014</study_first_submitted>
  <study_first_submitted_qc>February 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2014</study_first_posted>
  <last_update_submitted>October 12, 2020</last_update_submitted>
  <last_update_submitted_qc>October 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adult patients</keyword>
  <keyword>Immune primary thrombocytopenia</keyword>
  <keyword>Splenectomy</keyword>
  <keyword>TPO-mimetics</keyword>
  <keyword>Eltrombopag</keyword>
  <keyword>Romiplostim</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

